REGENXBIO to Present at Upcoming Investor Conferences
Fireside Chat: Wednesday, May 12, 2021 at
Fireside Chat: Tuesday, May 18, 2021 at
A live webcast of each fireside chat can be accessed in the 'Investors' section of
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV® Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Investor Relations and Corporate Communications
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-upcoming-investor-conferences-301285276.html